Printer Friendly

CEPHALON PRESENTS SIGNIFICANT DISCOVERY IN ALZHEIMER'S DISEASE PROGRAM

 WEST CHESTER, Pa., Oct. 7 /PRNewswire/ -- Cephalon Inc. (NASDAQ: CEPH) announced today the discovery of small molecule compounds which in preclinical studies act to inhibit proteases (or enzymes) believed to be involved in the process of Alzheimer's disease progression.
 In this process, proteins, termed beta-amyloid peptides, are generated and may eventually form aggregates, leading to neuritic plaques. Cephalon's protease inhibitors are designed to prevent the generation of beta-amyloid peptide and may thus inhibit neuritic plaque formation, a diagnostic hallmark of Alzheimer's disease. Robert Siman, Ph.D., Cephalon's Senior Director of Biochemistry, presented these data from the company's Alzheimer's disease program today at the IBC Conference on Neurodegenerative Diseases in Lake Buena Vista, Fla.
 "Current research strongly suggests that Alzheimer's may in part result from the destruction of nerve cells via the formation of beta- amyloid deposits or plaques in the brain," explained Dr. Siman. "One pathway by which these plaques develop is through the activity of proteases that generate beta-amyloid peptides from a family of precursor proteins. We therefore expect that by inhibiting these proteases we will be able to prevent the further degeneration of nerve cells that lies at the root of this relentless disease."
 Beta-amyloid is generated by the activity of a protease on a family of amyloid precursor proteins. Inhibition of these proteases should inhibit the generation of beta-peptide and, perhaps, the formation of plaques.
 "Today's presentation describes novel protease inhibitors that significantly suppress beta-amyloid generation," stated Dr. Frank Baldino Jr., president and CEO of Cephalon. "The Alzheimer's disease program has been the cornerstone of our therapeutic approach to chronic, degenerative diseases. The identification of lead agents in our program to develop therapeutic small molecules to treat Alzheimer's disease represents a major advance."
 Alzheimer's disease is a chronic and progressively incapacitating disease characterized by the death of several types of neurons in the brain. Associated with severe dementia in patients, Alzheimer's disease afflicts more than 4 million Americans. The age-dependent nature of the disorder indicates that an ever-increasing percentage of Americans will be affected as the population ages. There are no therapies available today which alter the course of this disease.
 Since l99O Cephalon and Schering-Plough Corporation have been collaborating in this program to develop and commercialize products to treat Alzheimer's disease.
 Cephalon, Inc. is a leader in the discovery and development of products to treat neurological diseases and disorders. The company's principal focus is on neurodegenerative diseases such as ALS, peripheral neuropathy, Alzheimer's disease, head and spinal cord injury, and stroke.
 /delval/
 -0- 10/7/93
 /CONTACT: Jason Rubin or Lyn Hyduke, Corporate Communications, of Cephalon, 2l5-344-0200, or Karen Bergman, of Burns McClellan, 212-505-l9l9/
 (CEPH)


CO: Cephalon Inc. ST: Pennsylvania IN: MTC SU:

MJ-CC -- PH003 -- 1241 10/07/93 09:08 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 7, 1993
Words:456
Previous Article:SEPTEMBER SALES INCREASE 9.3 PERCENT FOR THE MAY DEPARTMENT STORES COMPANY
Next Article:AMERICAN RESIDENTIAL POSTS $914 MILLION IN SEPTEMBER LOAN ORIGINATIONS; YEAR-TO-DATE ORIGINATIONS EXCEED CALENDAR 1992 LEVEL
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters